Clinical trials / NCT06183359
Recruiting

Self-Identification Program

Conduct a pilot, single-center, randomized controlled 2-arm study aimed to evaluate the impact of an in-depth 3rd wave CBT program targeting correct self-identification (3rd level of 3rd wave CBT), compared to a control group receiving an acceptance and commitment therapy (ACT; (1st level of 3rd wave CBT, a well-known psychotherapy). Main judgment criteria : Therapeutic response (reduction ≥ 50% between pre and immediate post-treatment), and rate of relapse at 6 months post-therapy. Secondary objectives: Evaluate…

I'm interested View official listing
ClinicalTrials.gov IDNCT06183359
PhaseNA
Enrollment86
SponsorUniversity Hospital, Montpellier
Age18 Years and older
SexALL
I'm interested View official listing

Conditions studied

Major Depressive Disorder, Third Wave Cognitive Behavioral Therapy

About this study

Conduct a pilot, single-center, randomized controlled 2-arm study aimed to evaluate the impact of an in-depth 3rd wave CBT program targeting correct self-identification (3rd level of 3rd wave CBT), compared to a control group receiving an acceptance and commitment therapy (ACT; (1st level of 3rd wave CBT, a well-known psychotherapy). Main judgment criteria : Therapeutic response (reduction ≥ 50% between pre and immediate post-treatment), and rate of relapse at 6 months post-therapy. Secondary objectives: Evaluate psychological processes involved in the reduction of moral pain, diligence, ruminations, suicidal ideas, self-concept and alterations in functioning (mental and social), psychological skills.

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: * Patients aged 18 to 70 years, presenting a current major depressive episode (according to DSM 571), as part of unipolar or bipolar depressive disorder Exclusion Criteria: * Patients with a psychotic disorder * Patients with active thoughts of suicide with intention to carry out the act (C-SSRS "ideation suicidal" in the last week ≥ 4) * Inability to receive informed information about the study * Exclusion period determined by a previous study * Adult protected by law or patient under guardianship or curatorship * Not be affiliated to a French social security scheme or beneficiary of such a scheme * Not being able to give informed written consent * Pregnant or breastfeeding women * Patients under judicial protection

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.